Supira Medical, Inc., A Shifamed Portfolio Company, Receives Fda Breakthrough Device Designation As The Company Closed $40M In Series D Financing

Supira Medical, Inc., a Shifamed portfolio company, announced today that it has received U.S. Food and Drug Administration (FDA) breakthrough device designation for its Supira System, a next-generation percutaneous ventricular assist device (pVAD). This approval comes as the company closed $40M in Series D financing and prepares to initiate its U.S. clinical program